Squamous Non-Small Cell Lung Cancer Market

Squamous Non-Small Cell Lung Cancer: Pipeline Review, Developer Landscape and Competitive Insights, 2021-2031

  • Lowest Price Guaranteed From USD 5,499

  • Pages

  • View Count

Squamous Non-Small Cell Lung Cancer Market Overview

The “Squamous Non-Small Cell Lung Cancer: Pipeline Review, Developer Landscape and Competitive Insights, 2021-2031” report features an extensive study on the marketed, clinical and preclinical molecules available / being developed for the treatment of Squamous Non-Small Cell Lung Cancer.

This report provides an in-depth analysis of the product pipeline and developer companies, highlighting the current treatment practices, emerging drugs, and market share of the individual therapies. In addition to other elements, the study includes detailed assessment of the current market landscape, providing information about the product’s mechanism of action, dosage and administration, and pharmacological studies, regulatory milestones, and other development activities.

One of the key objectives of the report was to estimate the existing market size and the future opportunity of therapies for Squamous Non-Small Cell Lung Cancer, over the next decade. Based on multiple parameters, such as disease prevalence, anticipated adoption of the forecasted therapies and the likely selling price of such therapeutic products, we have provided informed estimates on the evolution of the market for the period 2021-2031.

This image highlights the context of Squamous Non small Cell Lung Cancer Market report. Over time, important advances in diagnosis and the development of versatile treatment options have translated into tangible improvements in the overall survival of lung cancer patients; several targeted therapies are being developed against squamous NSCLCs This image provides list of Squamous Non-small Cell Lung Cancer Targeting Therapies. Presently, more than 85 product candidates are being investigated for the treatment of metastatic or advanced squamous NSCLC patients, across different phases of development This image presents current market landscape of Squamous Non small Cell Lung Cancer Drugs. Majority of the therapies are being evaluated in early stages for delivery via a number of administration routes, either as monotherapies or in combination with other drug products

Scope of the Report

  • A detailed assessment of the therapeutic pipeline activity and therapeutic assessment of the products by development stage, type of therapy, route of administration, type of molecule, line of therapy, dose strength and dose frequency across the complete product development cycle, including all clinical and nonclinical stages.
  • Detailed drug profiles that are either approved or in late stages of development for the treatment of squamous non-small cell lung cancer have been presented, featuring overview of the company, overview of the drug, clinical trial information, recent developments (such as clinical trial results, collaborations and conferences) and estimated sales revenue.
  • A detailed analysis identifying the key opinion leaders (KOLs), featuring a 2X2 analysis to assess the relative experience of certain KOLs who were shortlisted based on their contributions (in terms of involvement in various clinical studies) to this field.
  • An analysis of the partnerships that have been established in the domain, over the last five years, covering research agreements, product / technology licensing agreements, mergers / acquisitions, asset purchase agreements, R&D and commercialization agreements, IP licensing agreements, clinical trial agreements, product development agreements, and other relevant deals.
  • A detailed analysis of completed, ongoing and planned clinical studies, based on the various relevant parameters, such as trial registration year, trial phase, number of patients enrolled, study design, trial recruitment status, and trial focus, highlighting leading sponsors, type of organization, and regional distribution of trials. In addition, it features an insightful clinical end-points analysis.
This image presents current market landscape of Squamous Non small Cell Lung Cancer Market Therapy Developers. Over 55 companies, including a mix of small players and veterans in the pharma industry, are engaged in the development of squamous NSCLC therapies This image highlights competitive analysis of players engaged in the domain of Squamous Non small Cell Lung Cancer Drugs and Therapies. In pursuit of gaining a competitive edge, firms based in North America are actively investing, in terms of both resources and capital, to conduct R&D of squamous NSCLC targeting therapies This image highlights the partnership activity undertaken by players engaged in Squamous Non small Cell Lung Cancer Market. There has been a rise in partnership activity reported within this domain, in recent years; most of the deals were inked for product development and commercialization of biologics

Key Questions Answered

  • What are the prevalent R&D trends related to squamous non-small cell lung cancer?
  • What are the key challenges faced by stakeholders engaged in this domain?
  • What are the principal therapies developed by the companies in this domain?
  • Who are the leading industry and non-industry players in this market?
  • What are the contributions of big pharma players in this field?
  • What are the key geographies where research on squamous non-small cell lung cancer is being conducted?
  • Who are the key investors in this domain? 
  • Who are the key opinion leaders / experts in this field?
  • What kind of partnership models are commonly adopted by industry stakeholders? 
  • What are the factors that are likely to influence the evolution of this upcoming market?
  • How is the current and future market opportunity likely to be distributed across key market segments?
This image describe the analysis of identifying the key opinion leaders engaged in this field. A number of scientists from renowned universities, who are presently involved in the clinical development efforts in this field of research emerged as key opinion leaders This image provides information on the current and future market trends and potential growth of Squamous Non small Cell Lung Cancer Market. The current market size is estimated to be USD 1.4 billion; this value is projected to reach USD 2.8 billion in 2026; monoclonal antibodies are expected to contribute to a significant share of the total revenues This image highlights the market segments of Squamous Non small Cell Lung Cancer Market. The overall market opportunity for squamous NSCLC targeting therapies is likely to be distributed across different types of therapies, routes of administration and key geographical regions


This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print Read more about Single-User License

This license grants the right of use of the purchased report by the employees of a business unit at a particular site/office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple Read more about One Location Site License

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm/enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the Read more about Enterprise License

Discounts available for multiple report purchases
Click here to send an email to Roots Analysis team. sales@rootsanalysis.com